Artwork

Innhold levert av Talking About Tumors. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Talking About Tumors eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

05_01 Hepatocellular carcinoma

32:13
 
Del
 

Manage episode 456452588 series 3335024
Innhold levert av Talking About Tumors. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Talking About Tumors eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

1. Etiologies and epidemiology
2. Staging and local/regional considerations
3. Systemic Therapy
4. Differences in immune checkpoint sensitivity by etiology

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1. Finn RS, et al. Oncologist. 2022;27(12):E938-E948. doi:10.1093/ONCOLO/OYAC183

2. Pfister D et al. Nature 2021 592:7854. 2021;592(7854):450-456. doi:10.1038/s41586-021-03362-0

3. Zhu AX et al. Lancet Oncol. 2019;20(2):282-296. doi:10.1016/S1470-2045(18)30937-9

4. Abou-Alfa GK, et al. NEJM Evidence. 2022;1(8). doi:10.1056/EVIDOA2100070

5. Kudo M, et al. Lancet. 2018;391(10126):1163-1173. doi:10.1016/S0140-6736(18)30207-1

7. Llovet JM, et al. NEJM. 2008;359(4):378-390. doi:10.1056/NEJMOA0708857

8. Reig M, et al.. J Hepatol. 2022;76(3):681-693. doi:10.1016/J.JHEP.2021.11.018

9. Cheng AL et al. J Hepatol. 2022;76(4):862-873. doi:10.1016/j.jhep.2021.11.030

10. Finn RS et al. NEJM. 2020;382(20):1894-1905. doi:10.1056/NEJMOA1915745/

11. Rose S, et al. Lancet. 2024;404(10453):656-657. doi:10.1016/S0140-6736(24)00800-6

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

49 episoder

Artwork
iconDel
 
Manage episode 456452588 series 3335024
Innhold levert av Talking About Tumors. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Talking About Tumors eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

1. Etiologies and epidemiology
2. Staging and local/regional considerations
3. Systemic Therapy
4. Differences in immune checkpoint sensitivity by etiology

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1. Finn RS, et al. Oncologist. 2022;27(12):E938-E948. doi:10.1093/ONCOLO/OYAC183

2. Pfister D et al. Nature 2021 592:7854. 2021;592(7854):450-456. doi:10.1038/s41586-021-03362-0

3. Zhu AX et al. Lancet Oncol. 2019;20(2):282-296. doi:10.1016/S1470-2045(18)30937-9

4. Abou-Alfa GK, et al. NEJM Evidence. 2022;1(8). doi:10.1056/EVIDOA2100070

5. Kudo M, et al. Lancet. 2018;391(10126):1163-1173. doi:10.1016/S0140-6736(18)30207-1

7. Llovet JM, et al. NEJM. 2008;359(4):378-390. doi:10.1056/NEJMOA0708857

8. Reig M, et al.. J Hepatol. 2022;76(3):681-693. doi:10.1016/J.JHEP.2021.11.018

9. Cheng AL et al. J Hepatol. 2022;76(4):862-873. doi:10.1016/j.jhep.2021.11.030

10. Finn RS et al. NEJM. 2020;382(20):1894-1905. doi:10.1056/NEJMOA1915745/

11. Rose S, et al. Lancet. 2024;404(10453):656-657. doi:10.1016/S0140-6736(24)00800-6

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

49 episoder

All episodes

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett